Revance Therapeutics Inc (NAS:RVNC)
$ 3.04 -0.02 (-0.65%) Market Cap: 317.35 Mil Enterprise Value: 618.80 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Q4 2023 Revance Therapeutics Inc Earnings Call Transcript

Feb 28, 2024 / 09:30PM GMT
Release Date Price: $5.66 (-0.70%)
Operator

Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2023 financial results and corporate update conference call. (Operator Instructions) As a reminder, this call is being recorded on Wednesday, February 28, 2024. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations, Corporate Communications and ESG for events. Please go ahead.

Jessica Serra
Revance Therapeutics Inc - Head of Investor Relations and ESG

Thank you, operator. Joining us on the call today from Revance, our Chief Executive Officer, Mark Foley, and Chief Financial Officer, Toby Schilke. During this call, management will make forward-looking statements, including statements related to the impact of our pricing and strategy OnDeck's focus on adoption expectations and timing related to product adoption and reorders of pop product pipeline, consumer needs, preferences and behavior, the benefits and value to US practices and consumers of our products, including the efficacy, duration and safety of our products, 2024 guidance, cash flow breakeven,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot